ovarian cancer

[INmune Bio, Inc.] INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.

[Cancer Science] Scientists showed that the bromodomain-containing protein 4 (BRD4) inhibitor JQ1 promoted the apoptosis of B16 melanoma cells by altering mitochondrial dynamics, thereby inducing mitochondrial dysfunction and increasing oxidative stress.

[Cancer Cell International] Long non-coding RNAs and miRs are differentially expressed in ovarian cancer (OC) cells and influence OC progression. Investigators explored the underlying roles of LINC00115 and miR-30a in OC.

[Oncogene] Investigators demonstrated that ZEB2, the transcription factor of epithelial–mesenchymal transition, was upregulated in ascites cells from high-grade serous ovarian cancer patients and in CD133+ cancer stem-like cells from epithelial ovarian cancer cell lines.

[Molecular Oncology] The authors observed that UCA1 a lncRNA previously reported to play an oncogenic role in several malignancies, is overexpressed in the chemoresistant ovarian cancer cell line OAW42-R compared to their chemotherapy sensitive counterpart OAW42.

[Oncogene] The authors described the role of the long non-coding RNA SPRY4 intronic transcript 1 (SPRY4-IT1) in cancer metastasis by mechanisms related to Staufen1-mediated mRNA decay, and found that high SPRY4-IT1 expression was associated with aggressiveness and poor outcome in human colorectal, breast and ovarian cancer tissues.